 |
1 Product |  |
0 Diseases | | 1 Product |
|
1 Trial |  |
5 News |  |
- | Temodex (temozolomide gel) / Belmedpreparaty, Double Bond Pharmaceutical
Trial completion date: TARGLIO: A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (clinicaltrials.gov) - Jul 6, 2023
P1, N=27, Not yet recruiting, Sponsor: Double Bond Pharmaceutical AB
Trial completion date: Aug 2025 --> Dec 2025
- | Temodex (temozolomide gel) / Belmedpreparaty, Double Bond Pharmaceutical
Trial completion date, Trial primary completion date: TARGLIO: A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (clinicaltrials.gov) - Jan 27, 2023
P1, N=27, Not yet recruiting, Sponsor: Double Bond Pharmaceutical AB
Trial completion date: Aug 2025 --> Dec 2025 Trial completion date: May 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Jun 2025
- | Temodex (temozolomide gel) / Belmedpreparaty, Double Bond Pharmaceutical
DBP International AB: Australiensisk patent för Temodex/SI-053beviljas https://t.co/6FB7TSLbVp (Twitter) - Oct 31, 2022
- || Temodex (temozolomide gel) / Belmedpreparaty, Double Bond Pharmaceutical
Trial completion date, Trial initiation date, Trial primary completion date: TARGLIO: A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (clinicaltrials.gov) - Apr 5, 2022
P1, N=27, Not yet recruiting, Sponsor: Double Bond Pharmaceutical AB
Trial completion date: May 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Jun 2025 Trial completion date: May 2023 --> May 2024 | Initiation date: Sep 2021 --> Sep 2022 | Trial primary completion date: Mar 2023 --> Mar 2024
- | Temodex (temozolomide gel) / Belmedpreparaty, Double Bond Pharmaceutical
New P1 trial: TARGLIO: A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (clinicaltrials.gov) - Jul 18, 2021
P1, N=27, Not yet recruiting, Sponsor: Double Bond Pharmaceutical AB